Ten63’s deal with Boehringer; Coya sets up agree­ment with Dr. Red­dy’s; Re­NA­gade’s lay­offs

Ten63 Ther­a­peu­tics’ drug dis­cov­ery deal with Boehringer In­gel­heim: The Durham, NC-based start­up, which is us­ing gen­er­a­tive AI to de­vel­op small mol­e­cule med­i­cines, said the agree­ment spans mul­ti­ple tar­gets and dis­ease ar­eas. Fi­nan­cial de­tails weren’t dis­closed. Ten63 in May an­nounced a $15.9 mil­lion Se­ries A and plans to de­vel­op drugs that tar­get the in­fa­mous c-Myc, a pro­tein fre­quent­ly im­pli­cat­ed in pan­cre­at­ic can­cer. A pre­vi­ous­ly undis­closed in­vestor from that round is Yosemite, the can­cer-fo­cused ven­ture cap­i­tal fund re­cent­ly launched by Reed Jobs, whose fa­ther and Ap­ple co­founder Steve Jobs died from pan­cre­at­ic can­cer. — Ryan Cross

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.